Evidence map›Paper›PMID 42181759›Full record

ArticleMedical mycology case reports2026

Oesophageal

Ethan X Tan, Brennan Collis, Natasha Holmes, Julie Lokan, Andrew Grigg

Abstract readCase Reports
In one paragraph

Article in Medical mycology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ethan X TanDepartment of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia.
Brennan CollisDepartment of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
Natasha HolmesDepartment of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
Julie LokanDepartment of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australia.
Andrew GriggDepartment of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oesophageal mucormycosis is an uncommon life-threatening opportunistic fungal infection usually managed with antifungal therapy and aggressive surgical debridement. We describe a 54-year-old male who developed oesophageal mucormycosis 3 months post-allograft for multiply-relapsed leukaemia. Surgery was not performed due to prohibitive perioperative risk. He received 6 weeks of intravenous Liposomal Amphotericin B followed by long-term isavuconazole. Serial endoscopy and PET/CT imaging demonstrated resolution of infection to 7 months post-transplant where he died from relapsed leukaemia. We demonstrate that antifungal therapy alone may be efficacious where surgery is contraindicated and highlight the utility of PET/CT imaging for staging and monitoring this disease.

Indexed as

Invasive fungal infectionMucormycosisPET scanTransplant infectious diseases

Identifiers

PMID42181759
PMCPMC13196299

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.